Investors Overview
We’re Delivering the Promise of Healthier Lives.
Our Company
Corporate Profile
CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
Stock Today
Headquarters
CURE Pharmaceutical
1620 Beacon Place
Oxnard, CA 93033
Phone:
Fax:
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Cure Pharmaceutical
Our Investor Presentation
Media
Recent Videos
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
Press Releases
Nicole Kidman and Sera Labs Inc., a CURE Pharmaceutical Company, Launch Seratopical Revolution and New Ad Campaign
The plant based, alcohol-free, non-CBD, anti-aging beauty line is available Wednesday, June 9 LOS ANGELES - Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today a new ad campaign and launch of Seratopical Revolution, a new clean,...
CURE Pharmaceutical Schedules Investor Webcast for Thursday, May 27, 2021
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time. Rob...
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021. First Quarter 2021 and...
CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility
LOS ANGELES - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification...
Nicole Kidman, Sera Labs Strategic Business Partner/Global Brand Ambassador and Nancy Duitch, Sera Labs Founder/CEO Headline Collision 2021 and Talk the Future of Beauty Technology
InStyle Magazine's Editor in Chief and Host of Ladies First, Laura Brown Moderated the Intimate ConversationLOS ANGELES - Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), headlined Collision 2021 and discussed the changing landscape of beauty,...
CURE Pharmaceutical Announces Successful Results From Initial Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies....
Management Team
Board of Directors
Robert Davidson
Chief Executive Officer, Director
Michael Redard
Chief Financial Officer
Nancy Duitch
Chief Strategic Officer and Director; CEO of Wholly owned subsidiary, The Sera Labs
Mark Udell
Chief Accounting Officer
Ruben King-Shaw Jr.
Chairman of the Board
Robert Davidson
Chief Executive Officer, Director
Nancy Duitch
Chief Strategic Officer and Director, CEO of Wholly owned subsidiary, The Sera Labs.
Joshua Held
Director
Gene Salkind, MD
Director
William Yuan
Chairman Emeritus
Key Contacts
Investor Relations
(805) 410-9962 ext. 4
investor@curepharma.com
Auditors
RBSM, LLP
805 3rd Avenue #1430
New York, NY 10022
Corporate Counsel
K&L Gates
10100 Santa Monica Blvd., 8th Fl.
Los Angeles, CA 90067